Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid1
Introduction
The production of opsonising antibodies to capsular polysaccharide (PS) is believed to be the major defence mechanism against Streptococcus pneumoniae (Pnc) [1]. Furthermore, passively acquired antibodies to Pnc PS have proven to be protective against both invasive disease and local infections like acute otitis media [2], [3]. Pnc PSs evoke a satisfactory antibody response in adults, but are mostly poorly immunogenic in young children [4], [5].
Haemophilus influenzae type b (Hib) polysaccharide conjugate vaccines have succeeded in decreasing the incidence of invasive Hib diseases and serve as a model for the development of pneumococcal conjugate vaccines. The outer membrane protein complex of Neisseria meningitidis (OMPC) [6], [7], a non-toxic mutant diphtheria toxin CRM197 [8], [9], [10], diphtheria toxoid (D) [11], [12] and tetanus toxoid (T) [13], [14] have been used as carrier proteins in the new conjugate vaccines. These vaccines are all immunogenic in infants; the concentration of antibodies against the vaccine serotypes increases significantly after a primary series of two or three injections. Furthermore, immunological memory can be induced, as shown by the prompt and strong response to booster vaccination during the second year of life.
In addition to the carrier protein, the PS content and the PS-to-protein ratio differ in various vaccines. An increase in the number of serotypes included, i.e. the valency of the vaccine, will result in an increase of the total PS content and, consequently, the amount of carrier protein required. An increase in protein content can be critical for the tetanus and diphtheria conjugates, because children receive these proteins in routine diphtheria–tetanus–pertussis vaccination and in Hib conjugate vaccine.
We have previously compared three doses (1, 3 and 10 μg of each polysaccharide) of tetravalent PncD (Pnc PSs conjugated to diphtheria toxoid) in infants [12]. There was a tendency towards a better response with high doses after a primary series, as has also been observed with another diphtheria toxin-based conjugate vaccine, PncCRM [10]. In contrast, tetanus toxoid-based conjugates may induce epitopic interference. Dagan et al. have shown that increasing doses of Pnc PS–tetanus toxoid conjugate (PncT) interfere with the antibody response induced by simultaneous administration of Hib–tetanus conjugate vaccine [14].
In this study we compared the anti-Pnc PS responses to three doses of tetravalent pneumococcal conjugate PncT in infancy, and evaluated immunologic memory by giving booster vaccination with PS vaccine. The persistence of antibody levels was followed until 3 years of age.
Section snippets
Subjects and methods
This study complied with the latest revision of the Declaration of Helsinki and followed the European guidelines for Good Clinical Practice. The protocol of this study was approved by the Ethics Committee of the National Public Health Institute, Helsinki, Finland and by relevant boards in each Health Center prior to initiation. Written informed consent was obtained from the parents prior to enrolment of their children.
Safety
One child in the PncT10 group was withdrawn from the study after the first injection because of marked adverse events. He had strong local reactions on both thighs (study vaccine and DTP–Hib vaccine injection sites) and also presented with high-pitch crying after vaccination. The serological and safety data after the first injection for this subject were included in the statistical analysis.
No other immediate or severe reactions causally related to the vaccine were noted. Local reactions at the
Discussion
We demonstrated that PncT vaccine is well tolerated and confirmed the recent finding [11] that PncT vaccine induces antibody response and immunological memory in infants. The four serotypes acted distinctly but similarly as seen in other Pnc conjugate vaccines [6], [7], [8], [10], [11], [12]; 14 and 19F were stronger immunogens than 6B and 23F. The dose of the PncT did not have any effect on the anti-pneumococcal polysaccharide response after the primary series. Diphtheria protein conjugates
Acknowledgements
Financial support was provided by Pasteur Mérieux Connaught. We want to thank Pirjo Tamminen, MD, Risto Tillikainen, MD, Taina Halminen, MD, personnel of the child health centers and families participating in this study for their collaboration and Catherine Revaux, RN, Pirjo-Riitta Saranpää, RN, Minna Koivuniemi, RN and Anna Myllymäki, RN, for their reliable and professional help. B. Ryall and R. MacMaster are appreciated for the preparation of the conjugate vaccines. The discussions with
References (17)
- et al.
Bacterial polysaccharide immune globulin for prophylaxis of acute otitis media in high-risk children
J Pediatr
(1993) - et al.
Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants
J Pediatr
(1996) - et al.
Natural and vaccine-related immunity to Streptococcus pneumoniae
J Infect Dis
(1986) - et al.
Evaluation of bacterial polysaccharide immune globulin for the treatment or prevention of Haemophilus influenzae type b and pneumococcal disease
J Infect Dis
(1992) - et al.
Antibody responses to pneumococcal vaccination in children younger than five years of age
J Infect Dis
(1983) - et al.
Antibody response to 14-valent pneumococcal capsular polysaccharide vaccine in preschool age children
Pediatr Infect Dis J
(1986) - et al.
Pneumococcal polysaccharide-meningococcal outer membrane protein complex conjugate vaccine is immunogenic in infants and children
J Infect Dis
(1995) - et al.
Pentavalent pneumococcal oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in infants
Pediatr Infect Dis J
(1996)
Cited by (64)
Pneumococcal conjugate vaccine dose-ranging studies in humans: A systematic review
2021, VaccineCitation Excerpt :The search identified 3791 articles; 1691 remained after de-duplication (Fig. 1). A total of 360 full texts were reviewed; 9 studies were included in the review [2,28,37–43] (Table 2). Of the nine, two studies involved adult populations [41,43], six involved paediatric populations [2,28,38–40,42] and one involved adult and paediatric populations [37].
Pneumococcal Conjugate Vaccine and Pneumococcal Common Protein Vaccines
2017, Plotkin's VaccinesVaccine Immunology
2017, Plotkin's VaccinesSingle-injection vaccines: Progress, challenges, and opportunities
2015, Journal of Controlled ReleaseCitation Excerpt :As a result, these particles release a larger proportion of their total dose during the first burst than do larger, similarly-prepared particles [184]. One study using bolus vaccine administration has shown that a smaller priming dose may aide in the formation of immune memory, so it may be desirable to keep this burst relatively small [185]. Subsequent release kinetics are dependent on a number of factors including the degradation properties of the encapsulating material and device geometry (a more complete list is included in Table 2).
Vaccine immunology
2012, Vaccines: Sixth Edition
- 1
Presented in part at the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 1995 and the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, September 1996.
- 2
Tel.: +33-1-47-958-021; fax: +33-1-47-958-000.